Glucagon, secreted from pancreatic islet a cells, stimulates gluconeogenesis and liver glycogen breakdown. The mechanism regulating glucagon release is debated, and variously attributed to neuronal control, paracrine control by neighbouring b cells, or to an intrinsic glucose sensing by the a cells themselves. We examined hormone secretion and Ca 2þ responses of a and b cells within intact rodent and human islets. Glucose-dependent suppression of glucagon release persisted when paracrine GABA or Zn 2þ signalling was blocked, but was reversed by low concentrations (1-20 lM) of the ATP-sensitive K þ (K ATP ) channel opener diazoxide, which had no effect on insulin release or b cell responses. This effect was prevented by the K ATP channel blocker tolbutamide (100 lM). Higher diazoxide concentrations (!30 lM) decreased glucagon and insulin secretion, and a-and b-cell Ca 2þ responses, in parallel. In the absence of glucose, tolbutamide at low concentrations (,1 lM) stimulated glucagon secretion, whereas high concentrations (.10 lM) were inhibitory. In the presence of a maximally inhibitory concentration of tolbutamide (0.5 mM), glucose had no additional suppressive effect. Downstream of the K ATP channel, inhibition of voltage-gated Na þ (TTX) and N-type Ca 2þ channels (x-conotoxin), but not L-type Ca 2þ channels (nifedipine), prevented glucagon secretion. Both the N-type Ca 2þ channels and a-cell exocytosis were inactivated at depolarised membrane potentials. Rodent and human glucagon secretion is regulated by an a-cell K ATP channel-dependent mechanism. We propose that elevated glucose reduces electrical activity and exocytosis via depolarisation-induced inactivation of ion channels involved in action potential firing and secretion. 
Introduction
Blood glucose levels are under the control of two hormones released from the pancreatic islets of Langerhans. Islet b cells secrete insulin when glucose is high, decreasing glucose production by the liver and increasing glucose storage in multiple tissues. Regulated insulin secretion is relatively well understood, involving the metabolic stimulation of electrical activity, Ca 2þ entry, and exocytosis [1] . Islet a cells secrete glucagon in response to decreased blood glucose, whereas elevated glucose levels suppress glucagon release. Glucagon is the principal factor stimulating glucose production by the liver. In diabetes, baseline glucagon release is elevated, and glucagon secretion in the low-glucose condition is blunted [2] [3] [4] . These effects contribute to chronic hyperglycaemia and to an increased risk for acute hypoglycaemic events.
The mechanism regulating glucagon secretion is poorly understood and remains hotly debated [5] . Glucagon release in rodents may be regulated by paracrine signals, including caminobutyric acid (GABA) [6, 7] , Zn 2þ [8] , and insulin [9, 10] . Conversely, glucose may suppress glucagon secretion through a direct effect on a-cell activity [11] [12] [13] [14] . There are also studies suggesting that glucagon secretion is under hypothalamic control [15, 16] . Human in vivo studies provide conflicting evidence regarding the control of glucagon secretion by paracrine or intrinsic regulation of a cells [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , and very little work has been done to examine this question in isolated human islets.
Islet a cells express ATP-dependent K þ (K ATP ) channels [9, 13, 14, 31, 32] that can be closed by ATP [9, 31] . Glucose increases intracellular free ATP in a cells [8, 10] , although reports vary as to the ability of glucose to inhibit a-cell K ATP channels [13, 31, 33] . Evidence from SUR1 À/À mice implicate K ATP channels as regulators of glucagon release [13, 34, 35] . However, because both a and b cells possess molecularly identical K ATP channels [36, 37] , it is not clear how K ATPmediated depolarisation would stimulate insulin secretion but suppress glucagon secretion. The answer may lie in the downstream machinery regulating electrical activity and Ca 2þ entry. Unlike b cells, a cells possess a large voltage-dependent Na þ current that is essential for glucagon release [14, 33] . We have previously proposed that the depolarisation-induced inactivation of this channel contributes to the cessation of action potential firing [14] . Additionally, activation of voltage-dependent Ca 2þ channels (VDCCs) is essential for Ca 2þ entry and a-cell function [38, 39] . Accordingly, the a-cell intracellular Ca 2þ ([Ca 2þ ] i ) oscillations (reflecting a-cell electrical activity) are suppressed in parallel with glucagon release by glucose [40] . Multiple VDCCs regulate glucagon release [14, [41] [42] [43] , although the N-type channels appear to be particularly important for glucagon release evoked by hypoglycaemia alone [33, 44, 45] , at least in mouse islets. This is in contrast to the b cell in which the L-type VDCC functionally predominates [46] .
We have now compared insulin and glucagon release and aand b-cell Ca 2þ responses in intact mouse, rat, and human pancreatic islets. We show that glucose retained the ability to suppress glucagon release from isolated islets during blockade of the Zn 2þ and GABA paracrine pathways, and in the absence of stimulated insulin secretion or b-cell Ca 2þ responses. Thus we now provide evidence in both rodent and human islets supporting the direct (intrinsic) glucose regulation of glucagon release from pancreatic a cells.
Results

Glucose Can Regulate Glucagon Secretion Directly
To examine a role for GABA and Zn 2þ as paracrine mediators of glucagon secretion, we examined the ability of the GABA A receptor antagonist SR-95531 and Zn 2þ chelation with Ca 2þ -EDTA to prevent the glucose-dependent suppression of glucagon release. Glucose, at concentrations (7 and 8.3 mM) just above the threshold for insulin release (see below), suppressed glucagon secretion from isolated mouse ( Figure  1A ) and rat islets ( Figure 1B ) by 60% (n ¼ 15, p , 0.001) and 57% (n ¼ 10, p , 0.001), respectively. In both mouse and rat islets, the ability of glucose to inhibit glucagon secretion persisted in the presence of Ca 2þ -EDTA (43% and 48%, n ¼ 10, p , 0.001, respectively) and SR-95531 (31% and 46%, n ¼ 8 and 10, p , 0.01 and p , 0.001, respectively) ( Figure 1) .
It is worth noting that in the presence of the GABA A antagonist, glucagon secretion was increased under both lowand high-glucose conditions, and furthermore, glucose was approximately 50% less effective in suppressing glucagon release from mouse islets (31% versus 60%, respectively) ( Figure 1A ). Additionally, somatostatin released from pancreatic d cells is suggested to be a potential paracrine regulator of glucagon secretion. However, the somatostatin receptor 2 (SSTR-2) antagonist PRL-2903 does not interfere with the ability of glucose (at 3 and 7 mM) to inhibit glucagon secretion from mouse islets [47] . Like the GABA A receptor 
Author Summary
Glucagon is a critical regulator of glucose homeostasis. Its major action is to mobilize glucose from the liver. Glucagon secretion from a cells of the pancreatic islets of Langerhans is suppressed by elevated blood sugar, a response that is often perturbed in diabetes. Much work has focused on the regulation of a-cell glucagon secretion by neuronal factors and by paracrine factors from neighbouring cells, including the important islet hormone insulin. In contrast, we provide evidence in support of a direct effect of glucose on a cells within intact rodent and human islets. Notably, our work implicates an a-cell glucose-sensing pathway similar to that found in insulin-secreting b cells, involving closure of ATPdependent K þ channels in the presence of glucose. Furthermore, we find that membrane depolarisation results in inhibition of Na þ and Ca 2þ channel activity and a-cell exocytosis. Thus, we propose that elevated blood glucose reduces a-cell electrical activity and glucagon secretion by inactivating the ion channels involved in action potential firing and secretion.
antagonist, however, PRL-2903 increased glucagon secretion in low-glucose conditions [47] . Thus, although the present data do not entirely rule out these pathways as modulators of glucagon secretion, glucose is clearly able to suppress glucagon secretion independently of these.
a-Cell K ATP Channels Regulate Glucagon Secretion
We next examined glucagon and insulin secretion during pharmacological manipulation of K ATP channel activity. Here we have examined the role of K ATP channels in intact islets by applying an indirect, but minimally invasive, technique. It would have been difficult (if not impossible) to study the effects of glucose on a-cell K ATP channel activity using the patch-clamp technique because of the smallness of the a-cell resting conductance (0.15 nS/pF in the absence of glucose, of which two thirds is attributable to K ATP channels) [13] . We have instead used increasing concentrations of diazoxide and tolbutamide to ''titrate'' the influence of K ATP channel activity on a-cell [Ca 2þ ] i and glucagon secretion. Increasing concentrations of the K ATP channel activator diazoxide demonstrated that moderate activation of K ATP channels (0.3-10 lM diazoxide) relieved the suppression of glucagon secretion from both mouse ( Figure 2A ) and rat ( Figure 2B ) islets. Stimulation of glucagon release was half-maximal at approximately 1 lM diazoxide, which is well below that required to inhibit insulin release, suggesting that ''reactivation'' of glucagon release was not secondary to reduced b-cell secretion. Increasing the concentration of diazoxide beyond 10 lM inhibited glucagon secretion in parallel with an inhibition of insulin release from both mouse and rat islets (Figure 2A and 2B) . When instead applied in the presence of 1 mM glucose (at which concentration glucagon secretion is stimulated), increasing diazoxide produced a monotonic inhibition of glucagon secretion ( Figure 2C ) with a halfmaximal inhibitory concentration (IC 50 ) that is much lower than what is seen under high-glucose conditions (;2 lM versus ;50 lM).
In the complete absence of glucose, when K ATP channels are expected to be open, the K ATP channel antagonist tolbutamide also produced a biphasic effect on glucagon release. Augmentation of glucagon secretion was seen at tolbutamide concentrations of up to 1 lM (stimulation being half-maximal at 0.1 lM), whereas inhibition was observed at higher concentrations ( Figure 2D ). Importantly, in the presence of a maximally inhibitory tolbutamide concentration (0.5 mM), glucose was unable to produce any further inhibition of glucagon release ( Figure 3A ). These data are inconsistent with the idea that b-cell secretion is the primary inhibitor of a-cell glucagon release. They also suggest that glucagon secretion is maximal within a ''window'' of intermediate K ATP channel activity.
To further investigate the role of a-cell K ATP channels as regulators of glucagon secretion, we studied islets from Kir6.2Y12X mice, which posses a Tyr12STOP mutation in the Kcnj11 gene, leading to premature termination of the K ATP channel pore-forming subunit [48] . At low-glucose concentrations, glucagon secretion from the Kir6.2Y12X islets was already suppressed compared with that from wildtype islets ( Figure 3B ), similar to the effect of glucose stimulation or pharmacological K ATP channel inhibition observed in Figures 2D and 3A . Consistent with a recent report [49] , higher glucose levels stimulated glucagon secretion, perhaps due to a direct effect of metabolism on secretion [33] . In wild-type islets, glucagon secretion exhibited a nadir at 5 mM glucose, and glucagon secretion at 20 mM glucose was 40% higher than at 5 mM glucose. Insulin secretion in the Kir6.2Y12X islets was elevated at low-glucose concentrations ( Figure 3C ), whereas glucose-stimulated insulin secretion was blunted. It is notable that the increase in glucagon release from the Kir6.2Y12X islets was coincident with increased insulin secretion, reinforcing the view that inhibition of glucagon is not mediated by a factor released by the b cells. Furthermore, in control islets, the inhibition of glucagon secretion is maximal at a concentration of glucose (5 mM) that is without stimulatory action on insulin secretion.
We next examined the function of a and b cells in situ by monitoring the [Ca 2þ ] i responses of single cells within intact mouse islets. These were functionally identified by their [Ca 2þ ] i response to 0.5, 2, and 11 mM glucose [50] . Glucose stimulation suppressed the [Ca 2þ ] i response of a cells by 51 6 3% (n ¼ 63 cells in 15 islets, p , 0.001) ( Figure 4A and 4B). The suppressive effect of glucose was alleviated (to 101 6 11% of initial values) by application of 2 lM diazoxide ( Figure 4A and 4B). This concentration of diazoxide was similar to that which produced maximal stimulation of glucagon secretion and much (;15-fold) lower than necessary to inhibit insulin secretion ( Figure 2B ) or b-cell [Ca 2þ ] i responses to glucose ( Figure 4A ).
K ATP Channels Regulate Human a-Cell Activity
Little work has been done to examine the mechanism of glucose-regulated glucagon secretion from isolated human islets [51] . Glucagon and insulin secretion from islets isolated from healthy donors was examined. Similar to above, glucagon secretion from human islets was suppressed by 58 6 3% (n ¼ 9, p , 0.05) upon raising the glucose concentration from 0 to 10 mM. Tolbutamide (200 lM) inhibited glucagon release by 43 6 14% (n ¼ 7, p , 0.05). At the same time, insulin secretion was increased 6.4-and 4.4-fold by glucose and tolbutamide stimulation, respectively ( Figure 5A ). Moderate re-activation of K ATP channels with 2 lM diazoxide antagonized the glucose-induced suppression of glucagon release (n ¼ 7, p , 0.01) ( Figure 5B). A 10-fold higher concentration of diazoxide had significantly less stimulatory effect (p , 0.001 versus 2 lM diazoxide), and in the presence of 200 lM diazoxide, glucagon secretion was not different from that observed in the absence of the K ATP channel activator. Importantly, the lowest concentration of diazoxide (2 lM), which produced the strongest stimulation of glucagon secretion, had no inhibitory effect on glucose-stimulated insulin secretion (n ¼ 5), whereas 20 and 200 lM produced partial or complete inhibition of insulin secretion. The GABA A receptor antagonist SR95531 had no effect on glucose-induced inhibition of glucagon secretion from human islets, and whole-cell voltage-clamp measurements indicate that human a cells, unlike human b and d cells, express few if any GABA A receptor Cl À channels (M. Braun, R.
Ramracheya, and P. Rorsman, unpublished data). Examination of the Ca 2þ responses of single a and b cells within intact human islets demonstrated that glucose decreased [Ca 2þ ] i by 62 6 3% (n ¼ 42 cells in 7 islets, p , 0.001) in a cells, and that this effect could be completely reversed by 2 lM diazoxide ( Figure 6A and 6B). Furthermore, the re-activation of a-cell [Ca 2þ ] i responses by diazoxide could be prevented by application of 100 lM tolbutamide, confirming the role of K ATP channels ( Figure 6C ). An analysis of the dose-response relationship to diazoxide demonstrated a maximally effective concentration of 1.7 lM (Figure 6D 
Na
þ Channels Regulate Low-Glucose-Stimulated Glucagon Secretion
The above data suggest that glucose-dependent inhibition of a-cell K ATP channels is involved in the suppression of glucagon secretion. It is not clear however, how K ATP channel inhibition and membrane depolarisation result in suppression of secretion. Unlike in b cells, a-cell Na þ channels are active in the physiological range of membrane potentials. Previous work from our group suggested that the voltagedependent inactivation of Na þ channels, which in mouse a cells is half-maximal at À42 mV [43] , contributes to cessation of electrical activity upon a-cell depolarisation [14] . We thus used the voltage-dependent Na þ channel antagonist tetrodotoxin (TTX) to test a role for these channels in a-cell function and glucagon secretion. TTX (0.1 lg/ml) suppressed glucagon release from mouse islets by 56 6 5% (n ¼ 10, p , 0.001) under low-glucose conditions ( Figure 7A ). This effect of TTX in the low-glucose condition was similar to what we observed with high-glucose stimulation alone. With TTX present, glucose was without further inhibitory action, suggesting that glucose inhibits glucagon secretion through a Na þ channeldependent mechanism. TTX has no effect on glucosestimulated insulin secretion in mouse islets ( Figure 7A ); again suggestive of a direct rather than indirect effect on a cells. In accordance with this, application of 0.1 lg/ml TTX to mouse islets reversibly abolished the a-cell VDCCs allows Ca 2þ into a cells, triggering the exocytosis of glucagon-containing vesicles. We applied whole-cell patchclamp recordings to establish the a-cell Ca 2þ channel complement. The integrated whole-cell Ca 2þ current measured during 50-ms depolarisations from À70 mV to 0 mV amounted to 6.2 6 0.8 pC (n ¼ 15) under control conditions, 2.6 6 0.8 pC (n ¼ 10; p , 0.05) in the presence of 50 lM nifedipine, and 4.1 6 0.5 pC (n ¼ 12; p , 0.01) in the presence of 1 lM x-conotoxin. Thus, L-and N-type Ca 2þ channels account for 58% and 34% of the a-cell Ca 2þ current, respectively. Figure 8A compares glucagon secretion at 1 and 20 mM glucose under control conditions and in the presence of 100 nM x-conotoxin and 20 lM nifedipine, respectively. We found that whereas the L-type channel blocker nifedipine had no effect on glucagon release at 1 or 20 mM glucose, the N-type Ca 2þ channel blocker x-conotoxin inhibited the release of the hormone to a level similar to that of high glucose, tolbutamide, and TTX. Furthermore, glucose exerted no additional inhibitory action in the presence of xconotoxin. Thus, glucagon secretion stimulated by lowglucose levels depends principally on Ca 2þ influx through N-type channels, although these only account for one third of the Ca 2þ current. We confirmed this Ca 2þ channel dependence by conducting high-resolution single-cell capacitance measurements of exocytosis ( Figure 8B) . Exocytosis elicited by 500-ms step depolarisations from À70 to 0 mV averaged approximately 150 fF (corresponding to the fusion of ;75 secretory granules with the plasma membrane [43] ) under control conditions (Ctrl). This response was not significantly affected by 50 lM nifedipine (nif), but was nearly abolished by 1 lM x-conotoxin (x-con; Figure 8C ).
Inactivation of N-Type Ca 2þ Channels Underlie Glucose Inhibition of Glucagon Secretion
We next examined the mechanism by which N-type channels regulate glucagon release in response to membrane depolarisation/hyperpolarisation in mouse a cells. Non-Ltype (isradipine-resistant) Ca 2þ currents were elicited by step depolarization to 0 mV in the absence (black) or presence (red) of 1 lM x-conotoxin following a 200-ms conditioning pulse to À70 mV ( Figure 9A ) or þ10 mV ( Figure 9B ). It is evident that the x-conotoxin-sensitive component was abolished by the þ10 mV conditioning pulse. Figure 9C summarizes the relationship between the conditioning voltage and the Ca 2þ current amplitude in the absence (open squares) and presence (circles) of x-conotoxin (upper panel). The x-conotoxin-sensitive N-type Ca 2þ current component is shown in the lower panel of Figure 9C , and underwent voltage-dependent inactivation that was half-maximal (V 0.5 ) at À31 6 6 mV (n ¼ 6). A residual, x-conotoxin-insensitive Ca 2þ current also appears to undergo voltage-dependent inactivation ( Figure 9C ). This accounts for less than 15% of the inactivating current, and may be attributable to T-type Ca 2þ channels that have been reported in a cells [14] .
In Figure 9D , we examined the voltage-dependent activation of a-cell exocytosis using step-wise depolarisations (500 ms) from À70 mV to between À50 and 20 mV ( Figure 9D ). The capacitance response versus voltage relationship ( Figure 9E ) demonstrates a marked increase in the capacitance response between À10 and 10 mV. Thus any reduction in action potential amplitude within this range would severely attenuate a-cell exocytosis.
The voltage-dependent inactivation of a-cell exocytosis was examined next ( Figure 9F ). Cells were held at conditioning potentials between À70 and À30 mV, after which exocytosis was elicited by depolarisation to 0 mV. Exocytosis stimulated from the À30 mV conditioning potential was only 25% of that elicited from À70 mV ( Figure 9G ). This voltage-dependent inhibition of exocytosis appears to occur at more-negative voltages than that documented for the inactivation of the Ntype Ca 2þ channels can be attributed to the brevity of the conditioning pulses in Figure 9A -9C (200 ms), whereas in Figure 9G the holding potential was varied.
Discussion
Regulated glucagon secretion from pancreatic a cells is a major component of the counter-regulatory response to hypoglycaemia. Diabetes mellitus is associated with defects of glucagon secretion that exacerbate the consequences of impaired insulin secretion [2] [3] [4] . The mechanism regulating the release of this important hormone is incompletely understood and currently the source of much debate. In the present study we examined glucagon secretion and the [Ca 2þ ] i response of in situ a cells of isolated rodent and human islets. We further characterised the Ca 2þ currents and capacitance changes of single isolated a cells, to dissect the mechanism regulating downstream control of glucagon release.
Previous work with genetic mouse models, including SUR1 À/À [13, 34, 35] and Kir6.2 À/À [16] mice, suggests an important role for K ATP channels in glucagon secretion. Three pieces of evidence argue for the importance of islet K ATP channels in glucagon secretion. First, introduction of the Tyr12STOP mutation into the K ATP channel subunits in the Kir6.2Y12X islets results in suppression of glucagon secretion at low-glucose levels and causes loss of glucoseinduced inhibition of secretion. Second, the K ATP channel inhibitor tolbutamide when applied at maximally effective concentrations inhibits glucagon secretion from isolated islets. Third, a low dose of the K ATP channel activator diazoxide restores a-cell Ca 2þ responses and glucagon secretion in high-glucose conditions. What is not immediately clear from these arguments, and from the previous SUR1 À/À genetic studies, is whether glucagon is being controlled by the a-cell or the b-cell K ATP channels, as the latter may regulate acell function indirectly via paracrine pathways. We therefore examined insulin and glucagon secretion, and the Ca 2þ responses of a and b cells in situ in parallel to determine the functional relationship between these cells. Furthermore, we measured the glucagon response to glucose during blockade of putative paracrine signalling pathways.
Studies on rat islets support an important role for paracrine signals as regulators of glucagon release [33, 52, 53] , whereas the case for paracrine regulation of glucagon secretion from mouse and human a cells is less clear [9, 10, 14, [17] [18] [19] [20] [21] 27] . Although it is clear that Zn 2þ , GABA, and somatostatin can exert a paracrine control of glucagon secretion under certain conditions, the data shown here firmly establish that glucose can suppress glucagon secretion independently of these pathways as demonstrated in Figure 1 (and in [47] ). Furthermore, and in agreement with recently published results [47] , maximal inhibition of glucagon release occurs at levels equal to or lower than 5 mM glucose, whereas the stimulation of insulin release requires glucose levels greater than 5 mM (Figure 3) , suggesting that products of bcell secretion are not required for suppression of glucagon release.
This conclusion is further underpinned by the significant discordance between insulin and glucagon release, and the band a-cell Ca 2þ responses, under several conditions: (1) low doses of the K ATP channel opener diazoxide that stimulate glucagon secretion while not affecting insulin release; (2) high doses of diazoxide at which suppression of b-cell secretion would be expected to elevate glucagon release; (3) in the Kir6.2Y12X islets; and (4) in response to the Na þ channel blocker TTX. Therefore, our data argue that glucagonproducing a cells possess an intrinsic mechanism for regulation by glucose and that involves K ATP channels. This is at variance with the data of Liu et al. [12] who report that tolbutamide has no effect on [Ca 2þ ] i in single, isolated a cells, but in agreement with the conclusion of Ostenson et al. [54] , that sulfonylureas can inhibit glucagon secretion by a direct, non-paracrine mechanism.
On the basis of our findings, we propose that a-cell glucagon secretion occurs within a narrow window of intermediate K ATP channel activity (and thus membrane potential) ( Figure 10 ). That is, if the a cell is either too hyperpolarised (maximal K ATP activity) or too depolarised (maximal K ATP inhibition), then glucagon secretion is suppressed. This is supported by the biphasic effects of both diazoxide and tolbutamide. Whereas the former (in high glucose) brings the a cell in a dose-dependent manner through the membrane potential window supporting glucagon secretion in the depolarised (low K ATP ) to hyperpolarised (high K ATP ) direction (Figure 10C ), the latter (in zero glucose) brings the a cell through the window in the opposite direction (from hyperpolarised to depolarised) ( Figure 10B ). Thus, glucose likely leads to the suppression of glucagon secretion by depolarising the a-cell membrane potential above the range that supports glucagon secretion ( Figure  10A ). Indeed, in some (but not all, see [55] ) studies, glucose was found to depolarize mouse and rat a cells and reduce action potential amplitudes [13, 52] . It is interesting that whereas low concentrations of glucose were without stimulatory effect, tolbutamide (0.1-1 lM) stimulated glucagon release beyond that observed at zero glucose. Thus, small depolarisations (as previously documented for arginine [13] ) exert a positive ''chronotropic'' effect in a cells and thus stimulate glucagon release. The fact that glucose did not share this ability indicates that the depolarisation produced by 1 mM glucose results in sufficient inactivation of the currents to balance any increase in action potential frequency.
Previous human studies have employed pharmacological K ATP channel antagonists [23, 24] or agonists [25, 26] to examine the regulation of glucagon release in vivo. These were interpreted with the assumption that pharmacological K ATP modulation only affects the b cells, and that any change in glucagon release was therefore secondary to altered b-cell function. Our data establish that K ATP channel modulation has dramatic and direct effects on glucagon secretion and Ca 2þ signalling in human a cells under conditions in which insulin secretion is unaffected. Thus, the in vivo manipulation of a-cell K ATP channel activity in the above studies may well have involved direct effects on a-cell function that contributed to the observed changes in glucagon release. The importance of the human K ATP channel pathway for glucagon release is nicely highlighted by a study investigating the effects of the common Glu23Lys (E23K) polymorphism of the Kir6.2 subunit of the K ATP channel on insulin and glucagon secretion in non-diabetic human patients [29] . This variant of the channel leads to a slight decrease in the ATP sensitivity of the channel. The functional significance of this was examined by comparing hormone release during hyperglycaemic clamps in individuals carrying the polymorphism or not. Although insulin secretion in homozygous Glu23Lys individuals was not different from controls, glucose-induced suppression of glucagon release was blunted [29] . This becomes understandable in light of the effect of diazoxide on isolated human islets (Figures 4 and 5) . Half-maximal activation of K ATP channels occurs at diazoxide concentrations of 20-100 lM (depending on the intracellular ATP level) [56] . If the Glu23Lys polymorphism increases K ATP channel activity to the same extent as 0.3-1.5 lM diazoxide, the concentration at which an effect on glucagon release is first seen, then the effect will be very difficult to detect with electrophysiology, perhaps explaining why some studies have failed to detect a functional effect of the polymorphism (reviewed in [57] ). Nevertheless, such small changes can have significant biological effects, as illustrated by the glucagon release data, and may contribute to pathological states such as impaired glucose tolerance and diabetes. Thus, the reduced ability of glucose to inhibit glucagon secretion in individuals carrying the Glu23Lys variant of the K ATP channel likely results from the failure of these channels to undergo complete inhibition in response to glucose.
We have proposed that glucagon secretion is stimulated within a window of intermediate a-cell K ATP channel activity, and that glucagon release is suppressed by either increases or decreases in K ATP channel activity. How is this accomplished? Briefly, we suggest that this window is the result of (1) the ability of intermediate K ATP channel activity to support regenerative electrical responses through the activation of voltage-dependent Na þ and N-type Ca 2þ channels (grey in Figure 10 ); (2) the failure of the Na þ and Ca 2þ channels to activate when a cells are hyperpolarised by the opening of a major fraction of K ATP channels (above the grey in Figure 10) ; and (3) the voltage-dependent inactivation of the Na þ [14] and N-type Ca 2þ channels when K ATP channels are closed and the a-cell membrane potential is depolarised (below the grey in Figure 10 ). Thus, the differential responsiveness of a and b cells to diazoxide does not result from differential sensitivities of the K ATP channels in these cells, but to the downstream responses to titrated K ATP channel activity.
One important difference between mouse a and b cells is that whereas the latter rely exclusively on voltage-gated Ca channels. These channels undergo voltage-dependent inactivation at voltages more positive than À50 mV [14] . This will reduce the action potential amplitude, and indeed it is reported that glucose reduces the peak voltage in a cells from þ11 mV to À1 mV [13] . This will in itself result in an approximately 35% reduction of exocytosis, which is steeply dependent on voltage between À10 and þ10 mV ( Figure 9E ). The functional significance of this is illustrated by the observations that glucagon secretion and a-cell Ca 2þ responses at low-glucose concentrations are suppressed by the Na þ channel blocker TTX. The exact ion channel complement of human a cells remains to be established. However, the fact that glucagon secretion from human islets shows the same bell-shaped diazoxide concentration dependence as in mouse islets suggests that the depolarization-induced inactivation of ion channels involved in a-cell regenerative electrical activity underlies glucose-induced suppression of glucagon secretion in man as well. Although L-type VDCCs mediate the majority of Ca 2þ current in a cells, this work and previous studies [33, 44, 45] demonstrate that it is the N-type (x-conotoxin-sensitive) VDCCs that mediate the Ca 2þ influx necessary for a-cell exocytosis and glucagon secretion under hypoglycaemic conditions. We now show that the a-cell N-type VDCCs are also subject to voltage-dependent inactivation at voltages more positive than À50 mV and furthermore that this is associated with reduced exocytotic capacity. It is pertinent that N-type VDCC-deficient mice exhibit reduced serum glucagon levels and improved glucose tolerance despite a parallel reduction in plasma insulin [44] . Although Ca 2þ influx through L-type Ca 2þ channels does not appear to contribute much to glucagon secretion under the experimental conditions used in this study, these channels become the predominant conduit of Ca 2þ entry in the presence of agents increasing cAMP [41] (unpublished data). The mechanism underlying this switch in Ca 2þ channel dependence remains obscure, but may depend on the strength of depolarisation because glucagon secretion stimulated by strong depolarisation with increased K þ in combination with K ATP channel block can be prevented by inhibition of L-type Ca 2þ channels [47] . We finally point out that the model we propose here for the control of glucagon secretion shares many features with what is known about the metabolic control of insulin secretion. This in turn means that processes that interfere with the ability of, for example, glucose to stimulate insulin secretion will have the opposite effect on glucagon secretion. This would provide a simple explanation for the fact that both insulin and glucagon secretion become perturbed in diabetes and why oversecretion of glucagon exacerbates the hyperglycaemic effects of insufficient insulin secretion.
Materials and Methods
Islet isolation and culture. Islets from female NMRI mice were isolated by collagenase digestion and cultured in RPMI-1640 media (5 mM glucose) at 37 8C and 5% CO 2 for 2À24 h prior to secretion or intracellular Ca 2þ assays. For single-cell studies, islets were dispersed in a Ca 2þ -free buffer and plated in 35-mm plastic dishes. Generation of the Kir6.2Y12X mice, which possess a Tyr12STOP mutation in the Kcnj11 gene on a BALB/c background, has been described previously [48] . This results in nonfunctional K ATP channels in both a and b cells. These animals are not overtly diabetic, exhibiting normal fasting glucose, but are glucose intolerant (R. Cox, unpublished data). For these experiments, age-and weight-matched wild-type C3HB mice were used as controls because the Kir6.2Y12X mice were back-crossed into this background over several generations. Human islets from four healthy donors were obtained from the Oxford DRWF Human Islet Isolation Facility. Experiments were performed in duplicate or triplicate using islets from each donor. Human islets were cultured in RPMI-1640 (10 mM glucose) at 37 8C and 5% CO 2 , and experiments were performed within 48 h of isolation.
Intracellular Ca 2þ measurements. Intact islets were loaded with fluo-4-AM (1 lM) and fura red (5 lM) in 0.5 mM glucose buffer (see below) with 0.01% pluronic acid for 30 min at 37 8C. Islets were fixed with a wide-bore holding pipette within a continuously superfused and temperature-controlled (37 8C) bath on an Axioskop 2 FS-mot microscope (Carl Zeiss, http://www.zeiss.com). The perfusion buffer contained (in mM): 140 NaCl; 3.6 KCl; 2 NaHCO 3 ; 0.5 NaH 2 PO 4 ; 0.5 MgSO 4 ; 5 HEPES; 2.5 CaCl 2 ; 0.5, 3, or 11 glucose; (pH 7.4 with NaOH). Laser scanning confocal microscopy was performed using an LSM 510meta system (Zeiss). Excitation was with a 488-nm argon laser, and emitted fluorescence was collected through 500-550-nm and 650-710-nm band-pass filters for the fluo-4 and fura red (FuraR) signals, respectively. Increases in intracellular Ca 2þ are displayed as upward deflections. Images were acquired at 1.5-s intervals. Individual cells were selected as regions of interest, and the average ratio intensity (RI ¼ [Fluoþ1]/[FuraRþ20] 3 128þ1) of these were analysed over time with Origin v7.0220 (OriginLab Corporation, http://www.originlab.com). Prior to experimental recordings, islets were perfused for 10 min with the appropriate control solution, and Ca 2þ responses were monitored periodically during this time to ensure that responses (or lack thereof) were stable prior to beginning the experimental recording. Ca 2þ responses were determined by baseline subtraction and calculation of the integrated response (i.e., the area under the curve). The slope of this response, reported here as arbitrary units (AU), was calculated for the final 60%-90% of a given treatment period to allow for equilibration of the responses.
Hormone release. Insulin and glucagon secretion were measured as described elsewhere [45] . Briefly, batches of ten freshly isolated islets were pre-incubated in 1 ml of Krebs-Ringer buffer (KRB) supplemented with 1 mM glucose for 30 min (rodent) or 1 h (human) followed by 1-h incubation in 1 ml of test KRB medium supplemented as indicated. For experiments in which Zn 2þ was chelated or GABA A receptors were antagonised (Figure 1) , the Ca 2þ -EDTA and SR-95531, respectively, were present in both the pre-incubation and test solutions. When extracellular KCl was increased, NaCl was correspondingly reduced to maintain iso-osmolarity.
Single-cell capacitance and ion current measurements. Whole-cell currents and exocytosis were recorded using an EPC-9 patch-clamp amplifier (HEKA Electronics, http://www.heka.com) and Pulse software (version 8.50). Single a cells were identified by their small size and Na þ current inactivation properties [58] . This method was validated by combining the electrophysiological recordings with subsequent immunostaining for glucagon and insulin. The extracellular medium contained (in mM): 118 NaCl; 20 TEA-Cl (tetraethylammonium chloride); 5.6 KCl; 2.6 CaCl 2 ; 1.2 MgCl 2 ; 5 HEPES (pH 7.4 with NaOH); and 5 glucose. Except for Figure 8B and 8C, in which the standard whole-cell configuration was used, the electrophysiological measurements were conducted using the perforated patch technique, and the pipette solution contained (in mM): 76 Cs 2 SO 4 ; 10 NaCl; 10 KCl; 1 MgCl 2 ; and 5 HEPES (pH 7.35 with CsOH). Exocytosis was monitored as changes in a-cell capacitance using the software-based lock-in function of the Pulse software. The standard whole-cell measurements ( Figure 8B and 8C) were conducted using a pipette solution (dialyzing the cell interior) consisted of (in mM) 125 CsOH; 125 glutamate; 10 CsCl; 10 NaCl; 1 MgCl 2 ; 5 HEPES (pH 7.15 with KOH); 3 Mg-ATP; and 25 lmol/l EGTA (measured resting free Ca 2þ , ;0.2 lmol/l). Pulses were applied at low frequency (,0.05 Hz) to allow the exocytotic capacity to recover fully between the pulses.
Statistical analysis. Data are presented as means and standard errors. Significance was examined by either the unpaired t-test or by multiple-comparisons analysis of variance (ANOVA) and post-test, as appropriate.
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